
Sanofi halts global regulatory submission for amlitélimab in moderate to severe atopic dermatitis.
Sanofi has decided to stop the clinical development of amlitélimab, an antibody for moderate to severe atopic dermatitis, after strategic review showed insufficient efficacy and safety benefits. Despite some positive long-term results from the phase ...

